Physician profile
Devika Das
NPI 1922237486
$25,309.87
in general payments reported to CMS, 2019-2025
24 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,566 · 2022: $2,521 · 2023: $18.13 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $1,282 · Travel and Lodging: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,280.00 |
| Food and Beverage | $1,282.33 |
| Travel and Lodging | $660.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,589.55 | 2025 | |
| Lilly USA, LLC | $4,566.23 | 2019 | |
| Daiichi Sankyo INC. | $2,222.25 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $388.54 | 2022-2025 | Onglyza |
| Astellas Pharma US INC | $57.68 | 2025 | Vyloy |
| Janssen Biotech, INC. | $53.85 | 2025 | Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $49.13 | 2023-2025 | Keytruda, Keytruda Qlex |
| Abbvie INC. | $46.97 | 2025 | |
| Taiho Oncology, INC. | $33.11 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.04 | 2025 | Libtayo |
| Sobi, INC | $25.66 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.03 | 2025 | Opdivo |
| Genzyme Corporation | $24.70 | 2025 | |
| Agios Pharmaceuticals, INC. | $22.12 | 2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $20.64 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.42 | 2025 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $19.76 | 2025 | Fruzaqla |
| Adc Therapeutics America, INC. | $19.42 | 2025 | |
| Aveo Pharmaceuticals, INC. | $18.52 | 2025 | |
| Beone Medicines USA, INC. | $17.84 | 2025 | Tevimbra |
| Genmab U.S., INC. | $16.75 | 2025 | Epkinly |
| Legend Biotech USA INC. | $16.37 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $15.57 | 2025 | Clonoseq |
| Caris Mpi, INC. | $13.72 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.